NeoGenesis Pharmaceuticals
Cambridge
About NeoGenesis Pharmaceuticals
NeoGenesis Pharmaceuticals, Inc. is a drug discovery company which uses it proprietary affinity-based screening technologies and integrated chemical library and chemistry approaches to discover and develop a portfolio of small molecule drugs, both for itself and for its collaboration partners. The company's widely applicable and unbiased affinity-based technologies, coupled with its proprietary library of diverse drug-like compounds, provide efficiency in lead discovery and optimization, NeoGenesis' core technology, the Automated Ligand Identification System (ALIS), is a rapid, affinity-based system for identifying and optimizing novel drug leads that in many cases may not have been identified with traditional screening approaches. Coupled with the company's NeoMorph compound library, ALIS enables the identification and optimization of novel and selective drug leads against validated and emerging new targets. The company was founded in 1997 and is headquartered in Cambridge, Massachusetts.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $23.0M
- Funding stage: M&A
- Last round: Series Unknown (Jan 2001)
- Website: neogenesis.com
Industries & Categories
Biotechnology, Health Care, Medical, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/neogenesis-pharmaceuticals-2449602 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.